Skip to main content
European Commission logo

Health & life sciences

Low-cost sensors offer improved monitoring of air quality

Airborne pollutants are a threat to researchers and citizens alike. Using low-cost sensing technologies, the EU-funded VIDIS project hopes to deliver more accurate assessments of particulate matter exposure. Routine monitoring of air quality could offer significant health benefits for EU citizens.

Add to pdf basket

An app-based test for detecting synaesthesia in children

Synaesthesia, a neurological condition associated with anxiety disorders and autism, is difficult to identify in children. The EU-funded SYN-TOOLKIT project developed a new method to gather evidence of this perceptual phenomenon. The research has led to the development of a diagnostic smartphone app that could help these individuals access support.

Add to pdf basket

Pioneering biocompatible materials for implanted medical devices

Miniature medical devices have the potential to screen, monitor, diagnose and treat a range of body functions, conditions and diseases. But implanting these devices into the body requires safe, non-toxic materials. The biocompatible materials developed by the EU-funded BioWings project could open the door to a new era of medical innovation for EU citizens and the world.

Add to pdf basket

Researchers discover that viruses attack in sync to spread infection

It was assumed that viruses spread as independent particles called virions. The EU-funded Vis-a-Vis project used social evolution concepts to study viral transmission, showing how viral particles compete and collaborate with one another. An improved understanding of virus-virus interactions paves the way for a new generation of treatments.

Add to pdf basket

First drug against a blinding eye infection within reach

A rare infectious disease that can cause permanent blindness may soon have an approved treatment for the first time. A formulation of the molecule polihexanide, optimised by the EU-funded ODAK project, has been shown to cure 87 % of patients. The drug will soon be available to patients across Europe through an early access programme.

Add to pdf basket